Personalis combines world class expertise in the technology of genome sequencing and interpretation with an extensive track record of peer-reviewed publications to transform the development of next-generation cancer therapies by providing more comprehensive molecular data about each patient’s tumor.
The company completed an IPO in 2019.
Jonathan MacQuitty
FractionFraction
Faction Ventures, LLC (“Faction”) and Lightspeed Management Company, L.L.C. (“Lightspeed”) are separate businesses that operate independently of each other. Faction is a registered investment adviser under the United States Investment Advisers Act of 1940, as amended. Faction advises its own fund(s) and does not advise any Lightspeed clients, and Lightspeed does not advise Faction or any of its clients. Lightspeed and Faction are parties to an agreement pursuant to which Lightspeed holds certain interests in Faction and the fund(s) Faction manages.
